LDLR - low density lipoprotein receptor Gene
Species: Canis lupus familiaris (sub-species: familiaris)
Gene Type: protein coding
Gene ID: 100683160
LDLR Products (1)
| mRNA | Protein | Name |
|---|---|---|
| XM_038428592.1 | XP_038284520.1 | low-density lipoprotein receptor |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
low-density lipoprotein receptor |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-14668 | Lomitapide mesylate | Inhibitor | 99.61% | Yes |
| HY-B0374A | Moxonidine hydrochloride | 99.83% | Unkown | |
| HY-B0374 | Moxonidine | 99.72% | Unkown |
Clinical Phase
Bioactive Molecules
(8)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P4073 | ANG1005 | 98.83% | Phase 3 | |
| HY-124560 | Lifibrol | / | Phase 3 | |
| HY-152857 | Muvalaplin | Inhibitor | 99.96% | Phase 2 |
| HY-18778 | Obicetrapib | Inhibitor | 99.93% | Phase 2 |
| HY-109567 | Gemcabene | Inhibitor | 99.91% | Phase 2 |
| HY-109567A | Gemcabene calcium | Inhibitor | 98.0% | Phase 2 |
| HY-116175 | BIBB 515 | 99.56% | Phase 1 | |
| HY-172661 | Kylo-0603 | Inhibitor | / | Phase 1 |
Bioactive MoleculesInhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P99793 | Orticumab | Inhibitor | ≥99.0% | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(60)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-NP013 | Oxidized low density lipoprotein (mouse) | 98.00% | Unkown | |
| HY-P2341 | Angiopep-2 hydrochloride | 99.61% | Unkown | |
| HY-N0466 | Rebaudioside A | Activator | 98.0% | Unkown |
| HY-145001 | 20-HC-Me-Pyrrolidine | Inhibitor | 99.69% | Unkown |
| HY-W007347 | 1,2-Cyclohexanedione | 98.68% | Unkown | |
| HY-W015600 | 2-Acetamidophenol | Inhibitor | 99.73% | Unkown |
| HY-101529 | Imanixil | 99.29% | Unkown | |
| HY-N0627 | Kaempferol-7-O-β-D-glucopyranoside | 99.79% | Unkown | |
| HY-N0430A | Coptisine Sulfate | 99.37% | Unkown | |
| HY-158424 | LSN3353871 | Inhibitor | 99.62% | Unkown |
| HY-W018587 | TBPH | 95.0% | Unkown | |
| HY-P10502A | L57 acetate | 99.01% | Unkown | |
| HY-125544 | LY 295427 | Modulator | 98.0% | Unkown |
| HY-W015600S | 2-Acetamidophenol-d3 | 99.48% | Unkown | |
| HY-120651 | LDL-IN-2 | Inhibitor | 99.0% | Unkown |
| HY-P10502 | L57 | 99.44% | Unkown | |
| HY-P10697A | VH4127 TFA | Modulator | / | Unkown |
| HY-142026 | Vitisin A | Inhibitor | 96% | Unkown |
| HY-100144 | Pirozadil | 98.31% | Unkown | |
| HY-181997 | LDLRAP1-IN-1 | Inhibitor | / | Unkown |
| HY-W423578 | LDLR regulator-1 | Modulator | 99.89% | Unkown |
| HY-101812 | Terbufibrol | 98.39% | Unkown | |
| HY-A0127 | Etofibrate | Activator | 99.80% | Unkown |
| HY-N0430 | Coptisine | / | Unkown | |
| HY-130587 | Sultosilic acid piperazine salt | / | Unkown | |
| HY-U00054 | LDL-IN-3 | Inhibitor | / | Unkown |
| HY-159595 | PCSK9-IN-29 | Inducer | 99.44% | Unkown |
| HY-138089 | 17β-Hydroxy exemestane | Inhibitor | 98.21% | Unkown |
| HY-178335 | SGC-CK1γ-1 | Inhibitor | / | Unkown |
| HY-P11452A | (KKEEE)3K acetate | 98.13% | Unkown | |
| HY-176274 | FASN/SCD-IN-1 | Inhibitor | / | Unkown |
| HY-167870 | Piceatannol 4'-O-glucoside | Inhibitor | / | Unkown |
| HY-P11071 | PCSK9 Inhibitor, EGF-A | Degrader | / | Unkown |
| HY-167873 | Habenariol | Inhibitor | / | Unkown |
| HY-113288 | Campestanol | Inhibitor | 99.0% | Unkown |
| HY-P10911 | IETP2 | Ligand | / | Unkown |
| HY-105961 | F 2833 | Inhibitor | / | Unkown |
| HY-115914 | Lipid-lowering agent-1 | / | Unkown | |
| HY-147279 | Milpocitide | / | Unkown | |
| HY-P11452 | (KKEEE)3K | / | Unkown | |
| HY-P10698 | VH-N412 | / | Unkown | |
| HY-177291 | LAB687 | Inhibitor | / | Unkown |
| HY-P10697 | VH4127 | Modulator | / | Unkown |
| HY-N15706 | Luteolin-7-O-β-D-glucuronide methyl ester | / | Unkown | |
| HY-179459 | SJ-300 | Inhibitor | / | Unkown |
| HY-B0374AS | Moxonidine-13C,d3 hydrochloride | / | Unkown | |
| HY-172699 | DSPE-PEG2000-ANG | / | Unkown | |
| HY-18778B | Obicetrapib potassium | Inhibitor | / | Unkown |
| HY-161941 | MeIm | / | Unkown | |
| HY-P10697B | H-PEG6-VH4127-NH2 | / | Unkown | |
| HY-B0374S1 | Moxonidine-d7 | / | Unkown | |
| HY-18778A | Obicetrapib sodium | Inhibitor | / | Unkown |
| HY-126551 | Butenoyl-PAF | / | Unkown | |
| HY-B0374S2 | Moxonidine-d3 | / | Unkown | |
| HY-18778C | Obicetrapib hemicalcium | Activator | / | Unkown |
| HY-161938 | BRD8518 | / | Unkown | |
| HY-28911 | 2-Hydroxyacetaldehyde | Modulator | / | Unkown |
| HY-123260 | S12340 | Inhibitor | / | Unkown |
| HY-165512 | Nicanartine | Inhibitor | 99.36% | Unkown |
| HY-B0374S | Moxonidine-d4 | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(4)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990202 | Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) | Inhibitor | ≥95.0% | Unkown |
| HY-P99505 | Ziltivekimab | 99.75% | Unkown | |
| HY-P990143 | Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) | Inhibitor | 95.00% | Unkown |
| HY-P990480 | Anti-oxLDL Antibody | 96.99% | Unkown |